Evaluation of efficacy and safety of DPP-4 inhibitors for Chinese elderly patients with type 2 diabetes mellitus

Table 4 Comparison of height, weight and BMI before and after treatment with DPP-4 inhibitors

Index	Groups	Before treatment	After treatment	The change (ΔA)	P
Height (cm)	All patients	166.24 ± 7.34	166.17 ± 7.34	− 0.07	0.472
Weight (kg)	All patients	73.37 ± 10.16	71.96 ± 10.00	− 1.4	< 0.001
BMI (kg/m²)	All patients	26.50 ± 2.80	26.00 ± 2.80	− 0.5	< 0.001
Height (cm)	Medication time ≤ 12	160.46 ± 7.69	160.45 ± 7.82	− 0.01	0.989
Height (cm)	Medication time > 12	167.75 ± 6.44	167.66 ± 6.43	− 0.09	0.451
Weight (kg)	Medication time ≤ 12	66.61 ± 10.41	65.98 ± 10.90	− 0.63	0.171
Weight (kg)	Medication time > 12	75.13 ± 9.23	73.52 ± 9.06	− 1.6	< 0.001
BMI (kg/m²)	Medication time ≤ 12	25.87 ± 3.02	25.53 ± 3.08	− 0.34	0.065
BMI (kg/m²)	Medication time > 12	26.68 ± 2.69	26.13 ± 2.69	− 0.55	< 0.001
Height (cm)	eGFR ≥ 90 mL/min/1.73 m²	166.10 ± 7.76	166.05 ± 7.78	− 0.05	0.589
Height (cm)	eGFR < 90 mL/min/1.73 m²	166.46 ± 7.11	166.38 ± 7.11	− 0.08	0.582
Weight (kg)	eGFR ≥ 90 mL/min/1.73 m²	72.21 ± 11.08	70.69 ± 10.73	− 1.52	< 0.001
Weight (kg)	eGFR < 90 mL/min/1.73 m²	74.00 ± 9.62	72.66 ± 9.58	− 1.34	< 0.001
BMI (kg/m²)	eGFR ≥ 90 mL/min/1.73 m²	26.06 ± 2.77	25.51 ± 2.47	− 0.55	< 0.001
BMI (kg/m²)	eGFR < 90 mL/min/1.73 m²	26.70 ± 2.78	22.22 ± 2.93	− 4.48	< 0.001

ISSN: 1758-5996